Liquid Biopsy Market Overview
Globally, there has been a big increase within the number of people who have cancer. The rising prevalence of cancer are often attributed to many factors, like environmental factors, tobacco consumption, infectious agents like hepatitis b and C, and life style changes. according to the who, cancer is that the second-leading reason for death globally. International Agency for research on Cancer (IARC) estimated the worldwide cancer burden, indicating that it's up to nineteen.3 million cases and 9.96 million cancer deaths in 2020. Liquid biopsy holds many advantages over ancient cancer medicine techniques—reduced value, early prognosis, medical care traditional, detection of neoplasm nonuniformity, nonheritable drug resistance, and patient comfort (by eliminating the requirement for surgery). As a result, the preference for liquid diagnostic assay can probably rise within the forecast amount, proportional to the expansion in cancer prevalence.
Companion medicine embody tests or assays supposed to help aid suppliers in creating treatment choices for patients supported the most effective response to medical care. The co-development of companion medicine with therapeutic merchandise will considerably alter the drug development method and commercialize drug candidates by yielding safer medication with increased therapeutic effectualness quickly and cost-effectively. With the enhanced demand for costly specialist therapies and safer medication, the marketplace for companion medicine has high growth potential. The growing importance of companion medicine is additionally providing growth opportunities for the liquid biopsy market.
Detecting ctDNA in liquid biopsies is technically difficult as a result of the amount of ctDNA of any given cancer mutation is also terribly low within the plasma of a cancer patient, particularly once treatment or surgery. The sampling statistics mean that in any person sample of plasma from a patient, there is also but one detectable copy of the ctDNA with the cancer mutation. this could lead to the ctDNA not being detected within the patient sample, albeit it's gift within the plasma, however at a coffee level. This results in false-negative ends up in that ctDNA isn't detected albeit it's gift and impacts the informative worth of the liquid diagnostic assay tests for cancer. In some cases, false negatives might mean that the repeat of a neoplasm isn't detected at AN early stage.
| Report Metric | Details |
| Market size available for years | 2023–2030 |
| Base year considered | 2023 |
| Forecast period | 2024–2030 |
| Forecast unit | Value (USD Million) |
| Segments covered | Product, Application, End User and Region |
| Regions covered | North America (the U.S. and Canada), Europe (UK, Germany, France, Italy, Spain, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South East Asia, Rest of Asia Pacific), Latin America and the Middle East and Africa (Brazil, Saudi Arabia, UAE, Rest of LAMEA) |
| Companies covered | F. Hoffmann-La Roche Ltd., Myriad Genetics, Inc., QIAGEN N.V., Thermo Fisher Scientific, Inc., Guardant Health, Inc., MDxHealth SA, Exact Sciences Corporation, Illumina Inc., Sysmex Inostics, Bio-Rad Laboratories, Inc., Biocept, Inc., NeoGenomics, Inc., ANGLE plc, Menarini-Silicon Biosystems, Vortex Biosciences, Inc., Exosome Diagnostics, Inc., Agena Bioscience, Inc., MedGenome Inc., Epigenomics AG, Personal Genome Diagnostics, Inc. |
The covid-19 Impact on Liquid Biopsy Market:
Like several different industries, COVID-19 badly knocked the electronic and semiconductor trade. This new event has compact nearly 230 countries in exactly a couple of weeks, leading to the forced conclusion of producing and transportation activities at intervals and across the countries. This has directly affected the expansion of the sector. It's calculable that COVID-19 to depart over USD thirty billion impacts on the physics and semiconductor trade. The arena is majorly affected thanks to transport restrictions on major physics and semiconductor staple suppliers. However, the rising want for semiconductors in many industries can supply fast market recovery over the longer-term amount.
Liquid Biopsy Market Segment Overview
By Product, assay kits segment accounted for the largest share of the liquid diagnostic test market, by product & service, The liquid biopsy market is segmented into assay kits, instruments, and services based on product & service. The assay kits section accounted for the largest share of the liquid diagnostic test market in 2020. the standard purchase requirement of assay kits makes them a recurrent cost that is a key issue attributing to the growth of this section.
By Application, cancer application section accounted for the largest share within the market,The liquid biopsy market is segmented into cancer and non-cancer applications based on application. The cancer application section accounted for the largest share of the liquid diagnostic test market in 2020. Factors like the increasing prevalence of cancer and also the growing range of analysis studies on liquid biopsy for cancer applications square measure driving the growth of this segment.
By End User, reference laboratories segment accounted for the largest share within the market, The liquid diagnostic test market has been metameric into reference laboratories, hospitals and MD laboratories, tutorial & analysis centers, and different finish users. The reference laboratories section accounted for the largest share of the liquid diagnostic test market in 2020. The increasing outsourcing of liquid biopsy tests to reference laboratories is driving the growth of this segment.
Market Analysis, Insights and Forecast – By Product
· Assay Kits,
· Instruments,
· Service
Market Analysis, Insights and Forecast – By Application
· Cancer Application
· Non-cancer Applications
Market Analysis, Insights and Forecast – By End User
· Reference Laboratories
· Hospitals and Physician Laboratories
· Academic & Research Centers
· Other End Users
Liquid Biopsy Market Regional Overview
Region-wise, in terms of regions, North America accounted for the largest share of the liquid biopsy market. the massive share of this regional section is attributed to the easy accessibility to technologically advanced instruments, highly developed healthcare systems within the U.S. and canada, and presence of the many leading national clinical laboratories.
Liquid Biopsy Market, By Geography
· North America (US & Canada)
· Europe (UK, Germany, France, Italy, Spain, & Rest of Europe)
· Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
· LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)
Liquid Biopsy Market Competitor overview
Some key developments and strategies adopted by manufacturers in the Liquid Biopsy are highlighted below.
· In 2021, guardant Health, Inc. (US) launched its Guardant360 Response test that detects changes in circulating tumor DNA (ctDNA) levels.
Liquid Biopsy Market, Key Players
· F. Hoffmann-La Roche Ltd.
· Myriad Genetics, Inc.
· QIAGEN N.V.
· Thermo Fisher Scientific, Inc.
· Guardant Health, Inc.
· MDxHealth SA
· Exact Sciences Corporation
· Illumina Inc.
· Sysmex Inostics
· Bio-Rad Laboratories, Inc.
· Biocept, Inc
· NeoGenomics, Inc.
· ANGLE plc
· Menarini-Silicon Biosystems
· Vortex Biosciences, Inc.
· Exosome Diagnostics, Inc.
· Agena Bioscience, Inc.
· MedGenome Inc.
· Epigenomics AG
· Personal Genome Diagnostics, Inc.
Frequently Asked Questions (FAQ) :
Q1. What is the total CAGR expected to be recorded for the Liquid Biopsy market during the forecast period?
Liquid Biopsy market is expected to record a CAGR of ~ xx% during the forecast period
Q2. Which segment is projected to hold the largest share in the Liquid Biopsy Market?
Assays kits segment is projected to hold the largest share in the Liquid Biopsy Market
Q3. What are the driving factors for the Liquid Biopsy market?
The rising prevalence of cancer are often attributed to many factors, is key factors that boost the growth of the Liquid Biopsy market progressively.
Q4. Which Segments are covered in the Liquid Biopsy market report?
Product, Application, End User and Region, these segments are covered in the Liquid Biopsy market report.
Q5. Which are the prominent players offering Liquid Biopsy ?
F. Hoffmann-La Roche Ltd., Myriad Genetics, Inc., QIAGEN N.V., Thermo Fisher Scientific, Inc., Guardant Health, Inc., MDxHealth SA, Exact Sciences Corporation, Illumina Inc., Sysmex Inostics, Bio-Rad Laboratories, Inc., Biocept, Inc., NeoGenomics, Inc., ANGLE plc, Menarini-Silicon Biosystems, Vortex Biosciences, Inc., Exosome Diagnostics, Inc., Agena Bioscience, Inc., MedGenome Inc., Epigenomics AG, Personal Genome Diagnostics, Inc.
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
4. Key Insights
- 4.1. Key Emerging Trends – For Major Countries
- 4.2. Latest Technological Advancement
- 4.3. Regulatory Landscape
- 4.4. Industry SWOT Analysis
- 4.5. Porters Five Forces Analysis
5. Global Liquid Biopsy Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast – By Product
- 5.2.1. Assay Kits,
- 5.2.2. Instruments,
- 5.2.3. Service
- 5.3. Market Analysis, Insights and Forecast – By Application
- 5.3.1. Cancer Application
- 5.3.2. Non-cancer Applications
- 5.4. Market Analysis, Insights and Forecast – By End User
- 5.4.1. Reference Laboratories
- 5.4.2. Hospitals and Physician Laboratories
- 5.4.3. Academic & Research Centres
- 5.4.4. Other End Users
- 5.5. Market Analysis, Insights and Forecast – By Region
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Latin America, Middle East, and Africa
6. North America Liquid Biopsy Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 6.1. Key Findings / Summary
- 6.2. Market Analysis, Insights and Forecast – By Product
- 6.2.1. Assay Kits,
- 6.2.2. Instruments,
- 6.2.3. Service
- 6.3. Market Analysis, Insights and Forecast – By Application
- 6.3.1. Cancer Application
- 6.3.2. Non-cancer Applications
- 6.4. Market Analysis, Insights and Forecast – By End User
- 6.4.1. Reference Laboratories
- 6.4.2. Hospitals and Physician Laboratories
- 6.4.3. Academic & Research Centres
- 6.4.4. Other End Users
- 6.5. Market Analysis, Insights and Forecast – By Country
- 6.5.1. U.S.
- 6.5.2. Canada
7. Europe Liquid Biopsy Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 7.1. Key Findings / Summary
- 7.2. Market Analysis, Insights and Forecast – By Product
- 7.2.1. Assay Kits,
- 7.2.2. Instruments,
- 7.2.3. Service
- 7.3. Market Analysis, Insights and Forecast – By Application
- 7.3.1. Cancer Application
- 7.3.2. Non-cancer Applications
- 7.4. Market Analysis, Insights and Forecast – By End User
- 7.4.1. Reference Laboratories
- 7.4.2. Hospitals and Physician Laboratories
- 7.4.3. Academic & Research Centres
- 7.4.4. Other End Users
- 7.5. Market Analysis, Insights and Forecast – By Country
- 7.5.1. UK
- 7.5.2. Germany
- 7.5.3. France
- 7.5.4. Italy
- 7.5.5. Spain
- 7.5.6. Russia
- 7.5.7. Rest of Europe
8. Asia Pacific Liquid Biopsy Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 8.1. Key Findings / Summary
- 8.2. Market Analysis, Insights and Forecast – By Product
- 8.2.1. Assay Kits,
- 8.2.2. Instruments,
- 8.2.3. Service
- 8.3. Market Analysis, Insights and Forecast – By Application
- 8.3.1. Cancer Application
- 8.3.2. Non-cancer Applications
- 8.4. Market Analysis, Insights and Forecast – By End User
- 8.4.1. Reference Laboratories
- 8.4.2. Hospitals and Physician Laboratories
- 8.4.3. Academic & Research Centres
- 8.4.4. Other End Users
- 8.5. Market Analysis, Insights and Forecast – By Country
- 8.5.1. China
- 8.5.2. India
- 8.5.3. Japan
- 8.5.4. Australia
- 8.5.5. South East Asia
- 8.5.6. Rest of Asia Pacific
9. Latin America, Middle East, and Africa Liquid Biopsy Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 9.1. Key Findings / Summary
- 9.2. Market Analysis, Insights and Forecast – By Product
- 9.2.1. Assay Kits,
- 9.2.2. Instruments,
- 9.2.3. Service
- 9.3. Market Analysis, Insights and Forecast – By Application
- 9.3.1. Cancer Application
- 9.3.2. Non-cancer Applications
- 9.4. Market Analysis, Insights and Forecast – By End User
- 9.4.1. Reference Laboratories
- 9.4.2. Hospitals and Physician Laboratories
- 9.4.3. Academic & Research Centres
- 9.4.4. Other End Users
- 9.5. Market Analysis, Insights and Forecast – By Country
- 9.5.1. Brazil
- 9.5.2. Saudi Arabia
- 9.5.3. UAE
- 9.5.4. Rest of LAMEA
10. Competitive Analysis
- 10.1. Company Market Share Analysis, 2018
- 10.2. Key Industry Developments
- 10.3. Company Profile
- 10.4. F. Hoffmann-La Roche Ltd.,
- 10.4.1. Business Overview
- 10.4.2. Segment 1 & Service Offering
- 10.4.3. Overall Revenue
- 10.4.4. Geographic Presence
- 10.4.5. Recent Development
- 10.5. Myriad Genetics, Inc.
- 10.6. QIAGEN N.V.
- 10.7. Thermo Fisher Scientific, Inc.
- 10.8. Guardant Health, Inc.
- 10.9. MDxHealth SA
- 10.10. Exact Sciences Corporation
- 10.11. Illumina Inc.
- 10.12. Sysmex Inostics
- 10.13. Bio-Rad Laboratories, Inc.
- 10.14. Biocept, Inc.
- 10.15. NeoGenomics, Inc
- 10.16. ANGLE plc
- 10.17. Menarini-Silicon Biosystems
- 10.18. Vortex Biosciences, Inc.
- 10.19. Exosome Diagnostics, Inc.
- 10.20. Agena Bioscience, Inc.
- 10.21. MedGenome Inc.
- 10.22. Epigenomics AG
Data Library Research are conducted by industry experts who offer insight on industry structure, market segmentations technology assessment and competitive landscape (CL), and penetration, as well as on emerging trends. Their analysis is based on primary interviews (~ 80%) and secondary research (~ 20%) as well as years of professional expertise in their respective industries. Adding to this, by analysing historical trends and current market positions, our analysts predict where the market will be headed for the next five years. Furthermore, the varying trends of segment & categories geographically presented are also studied and the estimated based on the primary & secondary research.
In this particular report from the supply side Data Library Research has conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and SOFT) of the companies that active & prominent as well as the midsized organization
FIGURE 1: DLR RESEARH PROCESS
Extensive primary research was conducted to gain a deeper insight of the market and industry performance. The analysis is based on both primary and secondary research as well as years of professional expertise in the respective industries.
In addition to analysing current and historical trends, our analysts predict where the market is headed over the next five years.
It varies by segment for these categories geographically presented in the list of market tables. Speaking about this particular report we have conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and many more) of the major players active in the market.
Secondary ResearchSecondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and Friend’s study of the Global Extra Neutral Alcohol. It was also used to obtain key information about major players, market classification and segmentation according to the industry trends, geographical markets, and developments related to the market and technology perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, sec filings, journals, white papers, SOFT presentations, and company web sites.
Market Size EstimationBoth, top-down and bottom-up approaches were used to estimate and validate the size of the Global market and to estimate the size of various other dependent submarkets in the overall Extra Neutral Alcohol. The key players in the market were identified through secondary research and their market contributions in the respective geographies were determined through primary and secondary research.
Forecast Model
